Publications
Longitudinal Clinical Validation of the Northstar Response Using Methylated cDNA as a Dynamic Treatment Response Biomarker in Advanced Stage Gastrointestinal (GI) Cancers
Longitudinal Clinical Validation of the Northstar Response Using Methylated cDNA as a Dynamic Treatment Response Biomarker in Advanced Stage Gastrointestinal (GI) Cancers
Liquid biopsy to reveal colorectal cancer molecular subtype information from ctDNA epigenetics
Liquid biopsy to reveal colorectal cancer molecular subtype information from ctDNA epigenetics
Quantifying MLH1 promoter methylation via liquid biopsy
Quantifying MLH1 promoter methylation via liquid biopsy
Prevalence and characterization of ESR1 alterations detected with an ultra-sensitive, liquid-only CGP assay in a large breast cancer cohort
Prevalence and characterization of ESR1 alterations detected with an ultra-sensitive, liquid-only CGP assay in a large breast cancer cohort
Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling
Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling
Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates
Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates
Detection of a novel GNA11 processed pseudogene in chromosome 20 from cfDNA and implications for liquid biopsy
Detection of a novel GNA11 processed pseudogene in chromosome 20 from cfDNA and implications for liquid biopsy
Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay
Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay
Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring
Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring
Clinical Validation of the Northstar Response: A Novel Quantitative Methylation ctDNA Monitoring Assay for Advanced GI Cancer Treatment Response
Clinical Validation of the Northstar Response: A Novel Quantitative Methylation ctDNA Monitoring Assay for Advanced GI Cancer Treatment Response
Absolute quantification of cell-free DNA for prenatal genetics and oncology
Absolute quantification of cell-free DNA for prenatal genetics and oncology
Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC
Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC
Methylation-Based ctDNA Serial Monitoring Correlates with Immunotherapy Response in NSCLC
Methylation-Based ctDNA Serial Monitoring Correlates with Immunotherapy Response in NSCLC
A novel liquid biopsy assay with an 88% detection rate of genomic alterations across CNS tumors.
A novel liquid biopsy assay with an 88% detection rate of genomic alterations across CNS tumors.
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.
Analytical and clinical validity of Northstar Select, a quantitatively enhanced liquid biopsy assay for comprehensive genomic profiling of solid tumors
Analytical and clinical validity of Northstar Select, a quantitatively enhanced liquid biopsy assay for comprehensive genomic profiling of solid tumors
Clinical Validation of Northstar Response, a novel methylated ctDNA therapy response monitoring assay in patients with advanced GI cancer undergoing active treatment
Clinical Validation of Northstar Response, a novel methylated ctDNA therapy response monitoring assay in patients with advanced GI cancer undergoing active treatment
Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.
Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.
